Literature DB >> 26779870

Causes of hypogonadotropic hypogonadism predict response to gonadotropin substitution in adults.

J Rohayem1, N Sinthofen1, E Nieschlag1,2, S Kliesch1, M Zitzmann1.   

Abstract

Germ cell and Sertoli cell proliferation and maturation in human testes occur in three main waves, during the late fetal and early neonatal period and at early puberty. They are triggered by periods of increased activity of the hypothalamic-pituitary-gonadal (HPG) axis. In hypogonadotropic hypogonadism (HH), these processes are variably disturbed. The objective of this study was to explore whether success of gonadotropin replacement in HH men is predictable by the origin of HH, indicating time of onset and severity of GnRH/gonadotropin deficiency. The data of 51 adult HH patients who had undergone one cycle of hCG/FSH treatment were reviewed. Five groups were established, according to the underlying HH origin. Therapeutic success by final bi-testicular volumes (BTVs) final sperm concentrations (SC) and conception rates were compared and related to baseline parameters, indicative of the degree of HPG-axis disruption. Overall, BTVs rose from 13 ± 15 to 27 ± 15 mL, spermatogenesis was induced in 98%, with mean SCs of 15 ± 30 mill/mL, spontaneous pregnancies in 37% and additional 18% via intracytoplasmic sperm injection. Kallmann syndrome patients had the poorest responses (BTV: 16.9 ± 10 mL; SC: 3.5 ± 5.6 mill/mL), followed by patients with congenital/infancy-acquired multiple pituitary hormone deficiencies (MPHD) and patients with HH+absent puberty (BTV: 21 ± 14/24 ± 9 mL; SC: 5.5 ± 6.5/ 14.5 ± 23.8 mill/mL). HH men with pubertal arrest and with post-pubertally acquired MPHD had the best results (BTV: 36 ± 14/38 ± 16 mL; SC: 25.4 ± 34.2/29.9 ± 50.5 mill/mL). Earlier conception after 20.3 ± 11.5 months (vs. 43.1 ± 43.8; p = 0.047) of gonadotropin treatment with higher pregnancy rates (62% vs. 42%) was achieved in the two post-pubertally acquired HH subgroups, compared to the three pre-pubertally acquired. Therapeutic success was higher in patients without previously undescended testes, with higher baseline BTVs (pre- vs. post-pubertal HH: 5 ± 4 mL vs. 26 ± 16 mL; p < 0.0001) and higher baseline inhibinB levels (pre- vs. post-pubertal HH: 16.6 vs. 144.5 pg/mL; p = 0.0004). The cause of HH is a valuable predictor of outcome of gonadotropin replacement in adults.
© 2016 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  Sertoli cell proliferation; fertility; hCG/hMG; hypogonadotropic hypogonadism; rFSH

Mesh:

Substances:

Year:  2016        PMID: 26779870     DOI: 10.1111/andr.12128

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  12 in total

1.  Delayed treatment of undescended testes may promote hypogonadism and infertility.

Authors:  Julia Rohayem; Alessandra Luberto; Eberhard Nieschlag; Michael Zitzmann; Sabine Kliesch
Journal:  Endocrine       Date:  2017-01-09       Impact factor: 3.633

2.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

3.  Reproductive outcomes of microdissection testicular sperm extraction in hypogonadotropic hypogonadal azoospermic men after gonadotropin therapy.

Authors:  Yu-Kuang Chen; I-Shen Huang; Wei-Jen Chen; Chen-Yu Huang; Chi-Hong Ho; Eric Yi-Hsiu Huang; William J Huang
Journal:  J Assist Reprod Genet       Date:  2021-05-12       Impact factor: 3.357

4.  Effect of Recombinant Gonadotropin on Testicular Function and Testicular Sperm Extraction in Five Cases of NR0B1 (DAX1) Pathogenic Variants.

Authors:  Jordan Teoli; Vincent Mezzarobba; Lucie Renault; Delphine Mallet; Hervé Lejeune; Pierre Chatelain; Frédérique Tixier; Marc Nicolino; Noël Peretti; Sandrine Giscard D'estaing; Béatrice Cuzin; Frédérique Dijoud; Florence Roucher-Boulez; Ingrid Plotton
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-30       Impact factor: 5.555

5.  An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism.

Authors:  Eberhard Nieschlag; Pierre-Marc G Bouloux; Barbara J Stegmann; R Ravi Shankar; Yanfen Guan; Anjela Tzontcheva; Christine McCrary Sisk; Hermann M Behre
Journal:  Reprod Biol Endocrinol       Date:  2017-03-07       Impact factor: 5.211

6.  Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism.

Authors:  Mikkel Andreassen; Anders Juul; Ulla Feldt-Rasmussen; Niels Jørgensen
Journal:  Endocr Connect       Date:  2018-03-07       Impact factor: 3.335

Review 7.  Update on male reproductive endocrinology.

Authors:  Raul I Clavijo; Wayland Hsiao
Journal:  Transl Androl Urol       Date:  2018-07

Review 8.  Clinical Use of FSH in Male Infertility.

Authors:  Hermann M Behre
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-24       Impact factor: 5.555

9.  Use of Biosimilar Follicle-Stimulating Hormone in Asthenozoospermic Infertile Patients: A Multicentric Study.

Authors:  Maurizio De Rocco Ponce; Carlo Foresta; Rocco Rago; Alessandro Dal Lago; Giancarlo Balercia; Aldo Eugenio Calogero; Sandro La Vignera; Ilaria Cosci; Andrea Di Nisio; Andrea Garolla
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

Review 10.  Follicle-stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles.

Authors:  Daniele Santi; Pascale Crépieux; Eric Reiter; Giorgia Spaggiari; Giulia Brigante; Livio Casarini; Vincenzo Rochira; Manuela Simoni
Journal:  J Clin Med       Date:  2020-04-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.